Predicting poor response to anti-osteoporosis therapy: a machine learning model integrating clinical and novel biomarker data

Category	Detail
Condition	Osteoporosis
Key Mechanisms	Integration of clinical characteristics and novel biomarkers to predict treatment response.
Target Population	Patients aged 50-85 years with primary osteoporosis initiating standard anti-osteoporosis therapy.
Care Setting	Osteoporosis specialty clinic or orthopedics inpatient department.

Developed a predictive model using machine learning to identify high-risk patients for inadequate treatment response.
Identified eight independent predictors of poor treatment response.
Random Forest model showed superior predictive performance with AUC of 0.856 in training and 0.825 in validation.
Utilized SHAP values to interpret model significance, highlighting serum β-CTX as a key predictor.
Study supports personalized therapeutic decision-making in osteoporosis management.

Utilize dual-energy X-ray absorptiometry (DXA) for BMD assessment.
Incorporate clinical characteristics and novel biomarkers in the diagnostic process.

Initiate standard anti-osteoporosis treatment based on comprehensive risk assessment.
Consider individual patient characteristics and biomarkers for personalized therapy.

Evaluate treatment response through follow-up BMD and biomarker testing after 12 months.

Identify patients at high risk for inadequate treatment response prior to therapy initiation.

543 patients with primary osteoporosis.

Standard anti-osteoporosis therapy for 12 months with variability in treatment response.

Employ machine learning models to enhance prediction of treatment efficacy.
Integrate both clinical and biomarker data for comprehensive patient assessment.
Utilize predictive models to guide personalized treatment strategies.

Clinical Scorecard: Forecasting inadequate response to osteoporosis treatment: a machine learning approach combining clinical features and innovative biomarker information